医疗保健差异与乳腺癌、结肠癌和肺癌筛查覆盖政策之间的关系
本文评估CMS和USPSTF的覆盖政策如何影响乳腺癌、结肠癌和肺癌筛查中的结局差异,指出少数种族和低收入人群死亡率更高、筛查可及性不平等加剧差异,并提出六项政策调整选项以缩小差异。
要点
- 黑人在乳腺癌、结肠癌和肺癌中的死亡率最高约比白人高42%。
- CMS和USPSTF的覆盖政策影响筛查可及性并加剧结局差异。
- 作者提出扩展证据基础、降低筛查年龄阈值、CMS批准CT结肠成像覆盖等选项。
核心结论
- CMS和USPSTF可考虑修订其覆盖决策过程以缩小并可能消除结局差异。
研究设计与样本
- 本文为政策分析类文章,评估CMS和USPSTF覆盖政策对乳腺癌、结肠癌和肺癌筛查差异的影响。
临床应用与阅片要点
- 作者提出CMS和USPSTF可考虑扩展证据基础以纳入涉及较高风险人群的观察性研究。
- 作者提出可考虑降低筛查的年龄阈值以涵盖发病率差异。
- 作者提出CMS可考虑批准筛查CT结肠成像的覆盖,该检查甚至可提高对其他筛查试验的依从性。
- 作者提出可考虑澄清和简化指南。
- 作者提出可考虑支持改善筛查可及性的研究,并鼓励为少数种族和族裔群体开发更多导航服务。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Disparities in outcomes exist for breast, colon, and lung cancer among diverse populations, particularly racial and ethnic underrepresented minorities (URMs) and individuals from lower socioeconomic status. For example, blacks experience mortality rates up to about 42% higher than whites for these cancers. Furthermore, although overall death rates have been declining, the differential access to screening and care has aggravated disparities. Our purpose is to assess how the coverage policies of CMS and the United States Preventive Services Task Force (USPSTF) influence these disparities. Additionally, barriers are often encountered in accessing screening tests and receiving prompt treatment. To narrow, and potentially eliminate, outcomes disparities, CMS and USPSTF could consider revising their decision-making processes regarding coverage. Some options include (1) extending their evidence base to include observational studies that involve groups at higher risk; (2) lowering the threshold ages for screening to encompass differences in incidence; (3) CMS approving screening CT colonography coverage, which can even increase compliance with other screening tests; (4) clarifying and streamlining guidelines; (5) supporting research on improving access to screening; and (6) encouraging the development of more navigation services for URMs.
引用
- Berland LL, Monticciolo DL, Flores EJ, et al. Relationships Between Health Care Disparities and Coverage Policies for Breast, Colon, and Lung Cancer Screening. J Am Coll Radiol. 2019. PMID: 30947890. doi:10.1016/j.jacr.2018.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。